Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
China Pharma Holdings ( (CPHI) ) has shared an update.
On February 26, 2026, Hainan Helpson Medical & Biotechnology, a subsidiary of China Pharma Holdings, entered into a technology transfer agreement to acquire full ownership of an invention patent covering Prinsepia Utilis Esterol sublingual tablets and their preparation method from inventor Xiaoyan Zhang. Under the deal, the transferor or a designated third party will provide related R&D and regulatory services, and China Pharma will pay the $6.93 million purchase price by issuing 12.6 million restricted common shares at $0.55 per share to the non-U.S. seller, potentially expanding the company’s future specialty drug offerings and reinforcing its R&D-driven growth strategy.
The most recent analyst rating on (CPHI) stock is a Sell with a $0.79 price target. To see the full list of analyst forecasts on China Pharma Holdings stock, see the CPHI Stock Forecast page.
Spark’s Take on CPHI Stock
According to Spark, TipRanks’ AI Analyst, CPHI is a Neutral.
The score is held down primarily by very weak financial performance (large losses, extremely negative ROE, and negative cash flows) and bearish technicals (below major moving averages with negative MACD). Corporate actions provide some strategic positives (pipeline patents and capital-structure flexibility), but dilution/reverse-split risk and loss-making fundamentals keep the overall score low.
To see Spark’s full report on CPHI stock, click here.
More about China Pharma Holdings
China Pharma Holdings, Inc., through its wholly owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd., operates in the pharmaceutical and biotechnology sector. The company focuses on developing and manufacturing medical products, with an emphasis on leveraging patented drug technologies to enhance its product portfolio and presence in prescription drug markets.
Average Trading Volume: 58,958
Technical Sentiment Signal: Sell
Current Market Cap: $2.79M
See more insights into CPHI stock on TipRanks’ Stock Analysis page.